Recent Articles from GlobeNewswire
AREZZO, Italy, May 22, 2026 (GLOBE NEWSWIRE) -- Italpreziosi S.p.A. is pleased to announce its official inclusion in the LBMA Silver Good Delivery List, one of the most prestigious international standards in the precious metals industry.
By Italpreziosi · Via GlobeNewswire · May 22, 2026
By BIGC · Via GlobeNewswire · May 22, 2026
Geneva, Switzerland, May 22, 2026 (GLOBE NEWSWIRE) -- Yesterday, Global Liver Institute (GLI), in collaboration with the Egyptian Ministry of Health and Population, convened a high-level policy event, on the sidelines of the Seventy-Ninth World Health Assembly (WHA79) to translate this global policy milestone into coordinated action.
By Global Liver Institute · Via GlobeNewswire · May 22, 2026
MIAMI, May 22, 2026 (GLOBE NEWSWIRE) -- ARKAY is proud to announce the launch of its new 200 ml Mocktail Tetra Pack Collection, a convenient, ready-to-drink line created for today’s fast-moving consumers who are looking for great taste, portability, and alcohol-free options.
By Arkay Beverages Inc · Via GlobeNewswire · May 22, 2026
The largest cycling event in Slovenian history will bring 800 riders from 50+ countries to the roads of Slovenia — including Slovenian cycling stars Tadej Pogačar and Primož Roglič
By Slovenian Tourist Board · Via GlobeNewswire · May 22, 2026
Schiphol, May 22, 2026 - Aegon today announces that Jennifer Palmieri will join Aegon as Chief Human Resources Officer and member of Aegon’s Executive Committee, effective June 29, 2026. She will succeed Holly Waters who will retire as of June 1, 2026.
By Aegon Ltd. · Via GlobeNewswire · May 22, 2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
By OSE Immunotherapeutics · Via GlobeNewswire · May 22, 2026
FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026
By Frontline plc. · Via GlobeNewswire · May 22, 2026
VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS
By VALLOUREC · Via GlobeNewswire · May 22, 2026
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance.
By NervGen Pharma Corp. · Via GlobeNewswire · May 21, 2026
BEIJING, May 21, 2026 (GLOBE NEWSWIRE) -- Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time.
By Yimutian Inc. · Via GlobeNewswire · May 21, 2026
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions.
By Medline Inc. · Via GlobeNewswire · May 21, 2026
Global Down Syndrome Foundation Honored Sen. Shelley Moore Capito and Rep. Paul Tonko at Event that Featured Award-Winning Multiplatinum Artist Rachel Platten and Inclusive Dance Team
By Global Down Syndrome Foundation · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance, Inc. (Nasdaq: AGAE) (the “Company” or “AIFA”) today provided an update regarding the previously received notice from the Listing Qualifications Department of The Nasdaq Stock Market.
By All In FutureTech Alliance, Inc. · Via GlobeNewswire · May 21, 2026
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”).
By Liminatus Pharma Inc. · Via GlobeNewswire · May 21, 2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from its clinical studies, selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, are now available on ASCO’s official website. Three of the six studies have been selected for rapid oral presentations, and three as poster presentation. These abstracts report data from ongoing studies evaluating the company’s three lead drug candidates, including BCR-ABL inhibitor olverembatinib(HQP1351); Bcl-2 inhibitor lisaftoclax (APG-2575); and MDM2-p53 inhibitor alrizomadlin (APG-115).
By ASCENTAGE PHARMA GROUP INTERNATIONAL · Via GlobeNewswire · May 21, 2026
Award marks Rocket Lab's first satellite production program for geostationary orbit and continues a Space Systems Command program for development and delivery on orbit of two Heimdall prototype payloads by Rocket Lab Optical Systems
By Rocket Lab Corporation · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE:PHR) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.
By HUTCHMED (China) Limited · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Zillow Group, Inc. (“Zillow” or the “Company”) (NASDAQ:Z) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of York Space Systems Inc. (“York Space Systems” or the “Company”) (NYSE:YSS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Claritev Corporation (“Claritev” or the “Company”) (NYSE:CTEV) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Calix, Inc. (“Calix” or the “Company”) (NYSE:CALX) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ:OPCH) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
Fresno, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Mason Street Wealth Management, a leading financial services firm specializing in retirement planning, highlights its innovative vision-first financial strategy, designed to help individuals approaching retirement turn their ideal future into a structured, actionable plan. By prioritizing personal goals before financial products, the firm is redefining how retirement planning is approached in today’s evolving financial landscape.
By Mason Street Wealth Management · Via GlobeNewswire · May 21, 2026
A multi-year partnership centered on “Ultimate Connection” through music, technology, and unforgettable live experiences
By Anker Innovations · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 21, 2026
Greenville, NC, May 21, 2026 (GLOBE NEWSWIRE) -- Carolina Financial Services Group, a Registered Investment Advisor firm with more than 30 years of experience in the Greenville and eastern North Carolina region as well as in the entire East Coast, is addressing the critical need for retirees to mitigate taxation and healthcare costs through a specialized, tech-enabled planning process.
By Carolina Financial Services Group · Via GlobeNewswire · May 21, 2026
130 first-time exhibitors signal explosive growth across sports, gaming, and food & beverage, while industry heavyweights converged to shape the next wave of consumer products
By Global Licensing Group · Via GlobeNewswire · May 21, 2026
From immersive audio to smart home security, Anker Innovations' portfolio debuts breakthrough technology at annual showcase
By Anker Innovations · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (NASDAQ:ATEC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased POET Technologies Inc. (“POET” or the “Company”) (NASDAQ:POET) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
By Kirby McInerney LLP · Via GlobeNewswire · May 21, 2026
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP is delighted to announce yet another closing in Uzbekistan having secured funding from OeEB, the Development Bank of Austria, to support Asia Alliance Bank.
By Emerging Markets Global Advisory · Via GlobeNewswire · May 21, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Claritev (CTEV) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), an investigational small molecule inhibitor of LRRK2 (leucine-rich repeat kinase 2), in individuals with early-stage Parkinson’s disease. Results from the study show that BIIB122 did not slow the progression of Parkinson’s disease versus placebo, as measured by the primary endpoint of Time to Confirmed Worsening in the modified Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II and III combined score. Secondary endpoints also did not show a benefit with BIIB122. Exploratory biomarker endpoints demonstrated >90% kinase inhibition of peripheral LRRK2 (phosphoserine 935) and, in a cerebrospinal fluid (CSF) sub-study, up to approximately 30% reduction observed in a biomarker of LRRK2 activity (phosphorylated Rab10). Expected levels of BIIB122 in the blood and CSF were sustained across the study. BIIB122 was generally well tolerated with an acceptable safety profile. Based on these results, Biogen and Denali will discontinue further development of BIIB122 in idiopathic Parkinson’s disease. Denali will continue to independently conduct the Phase 2a BEACON study evaluating the small molecule inhibitor in carriers of a pathogenic LRRK2 variant.
By Denali Therapeutics Inc. · Via GlobeNewswire · May 21, 2026
Project Gravity provides advertisers and data owners with a neutral platform that onboards and activates their first party data across Google DV360, The Trade Desk, Meta, TikTok, Amazon, Magnite, and many other Samba partners
By Samba TV · Via GlobeNewswire · May 21, 2026
LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- nVent (NYSE: NVT), a global leader in electrical connection and protection solutions, today announced its participation in William Blairs 46th Annual Growth Stock Conference on Wednesday, June 3, 2026. Beth Wozniak, Chair and Chief Executive Officer, will present at 8:00 a.m. CST.
By nVent · Via GlobeNewswire · May 21, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In York Space Systems (YSS) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients
By Crescent Biopharma, Inc. · Via GlobeNewswire · May 21, 2026
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors
By Pliant Therapeutics, Inc. · Via GlobeNewswire · May 21, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Black Rock (BRCB) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data from two separate assessments of AKY-2519 – a clinical imaging and dosimetry assessment in patients with mCRPC and a clinical imaging assessment in patients with various solid tumor types – demonstrated robust tumor uptake and limited normal tissue exposure. These findings, which supported the advancement of a broad clinical development program for AKY-2519, will be presented in two poster presentations at the upcoming 2026 ASCO Annual Meeting, being held May 29 – June 2, 2026, in Chicago.
By Aktis Oncology Inc. · Via GlobeNewswire · May 21, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Commvault (CVLT) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sportradar (SRAD) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) non-classical mutations (NCMs). These data will be presented by Julia Rotow, M.D., Clinical Director, Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, at the 2026 American Society of Clinical Oncology® (ASCO®) Annual Meeting on Saturday, May 30, 2026, 1:15 PM-2:45 PM CDT.
By Black Diamond Therapeutics, Inc · Via GlobeNewswire · May 21, 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.
By Autolus Therapeutics plc · Via GlobeNewswire · May 21, 2026
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Equus Total Return, Inc. (NYSE: EQS) (“Equus” or the “Company”) reports net assets as of March 31, 2026, of $20.9 million. Net asset value per share increased to $1.50 as of March 31, 2026, from $1.19 as of December 31, 2025. Comparative data is summarized below (in thousands, except per share amounts):
By Equus Total Return, Inc · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 21, 2026
SAN FRANCISCO and SHENZHEN, China and ZHANGJIAJIE, China, May 21, 2026 (GLOBE NEWSWIRE) -- Hitch Open World AI Championships and Whale Dynamic today announced that their strategic partnership has entered full-scale delivery. Whale Dynamic will provide all Hitch Open competing teams with a centimeter-accurate 3D high-definition (HD) map covering the entire 10.77-kilometer Tianmen Mountain course—featuring 1,100 meters of elevation change and 99 consecutive hairpin turns—as the unified localization baseline for the Hitch Open World AI Racing Championships 2026, scheduled for June 25–26 in Zhangjiajie, China.
By Hitch Interactive · Via GlobeNewswire · May 21, 2026
ACHESON, Alberta, May 21, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or “the Company”) (TSX:NOA/NYSE:NOA) today announced the results of its Annual and Special Meeting of Shareholders held on May 20, 2026. Shareholders elected directors, approved the appointment of KPMG LLP as the independent auditors of the Company, approved a non-binding advisory vote regarding the Company’s approach to executive compensation and ratified an Advance Notice Bylaw. The following are the results of the votes held at the meeting:
By North American Construction Group Ltd. · Via GlobeNewswire · May 21, 2026
MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon’s pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005.
By Eikon Therapeutics, Inc. · Via GlobeNewswire · May 21, 2026
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile
By Remix Therapeutics · Via GlobeNewswire · May 21, 2026
Normalization of free light chains occurred by day 15 across all doses
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · May 21, 2026
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · May 21, 2026
MIAMI, May 21, 2026 (GLOBE NEWSWIRE) -- AerSale Corporation (NASDAQ: ASLE) (the “Company”), today announced that the Company’s Chief Financial Officer, Martin Garmendia will present at the 2026 Jefferies Aftermarket MRO Virtual Summit on Thursday, May 28, 2026 at 12:10 pm ET, as well as host investor meetings.
By AerSale Inc · Via GlobeNewswire · May 21, 2026
SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including a rapid oral presentation highlighting preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC).
By Legend Biotech USA Inc. · Via GlobeNewswire · May 21, 2026
HERNDON, Va., May 21, 2026 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI) announced that its board of directors approved a 2026 second quarter dividend of $0.16 per share on the company's common stock.
By Navient Corporation · Via GlobeNewswire · May 21, 2026
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 -
By Immuneering Corporation · Via GlobeNewswire · May 21, 2026
SAN MATEO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Asher Biotherapeutics (Asher Bio), a clinical-stage biotechnology company developing precisely-targeted immunotherapies for cancer, today announced two upcoming presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026 in Chicago.
By Asher Biotherapeutics, Inc. · Via GlobeNewswire · May 21, 2026
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care
By Bicara Therapeutics Inc. · Via GlobeNewswire · May 21, 2026
SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. The data will be presented in a poster presentation on May 30, 2026 at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois. Olema will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer.
By Olema Oncology · Via GlobeNewswire · May 21, 2026
ROSEVILLE, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics targeting the integrated stress response (ISR) to address cancer relapse, metastasis, and resistance, today announced that preliminary results from its ongoing Phase 1b study (NCT06234605) of HC-7366 in combination with WELIREG® (belzutifan), Merck’s (known as MSD outside of the United States and Canada) oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, will be presented in two poster presentations at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study is evaluating HC-7366, an activator of the ISR kinase GCN2, in patients with advanced clear cell renal cell carcinoma (ccRCC) whose disease progressed after prior PD-1/PD-L1 checkpoint inhibitor and VEGF-tyrosine kinase inhibitor (VEGF-TKI) therapy.
By HiberCell, Inc. · Via GlobeNewswire · May 21, 2026
BH-30643 has demonstrated encouraging clinical activity against diverse EGFR genotypes and on-target resistance in heavily pretreated Phase 1 dose escalation/backfill population with advanced EGFR-mutant NSCLC
By BlossomHill Therapeutics, Inc. · Via GlobeNewswire · May 21, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Atara (ATRA) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Coty To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · May 21, 2026
COLUMBUS, Ohio, May 21, 2026 (GLOBE NEWSWIRE) -- The favorable impact of the legislative reforms enacted in Florida is now benefiting consumers and making headlines. The reforms of 2022 began at a Special Session in April convened subsequent to Demotech’s open letter, which was released after the spring general session adjourned, without acting on the disparate, disproportionate litigation levels adversely impacting the availability and affordability of insurance in Florida’s residential property insurance market.
By Demotech, Inc. · Via GlobeNewswire · May 21, 2026
ONTARIO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CVB Financial Corp. (NASDAQ: CVBF) and its principal subsidiary, Citizens Business Bank, National Association (“CBB,” and together with CVBF, the “Company”), today announced a planned leadership transition as part of its ongoing commitment to strong governance and continuity. At the conclusion of the Company’s annual meeting on May 20, 2026, it was decided that Hal W. Oswalt will transition from his role as Chairman to Vice-Chairman of the Boards of CVBF and CBB. At the same time, the Company’s Board of Directors also elected current director and Vice-Chairman George A. Borba Jr. as Chairman of the Boards of CVBF and CBB. Mr. Borba and Mr. Oswalt will assume their respective new roles immediately.
By CVB Financial Corp · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 21, 2026
REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14, 2026, from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), to acquire all of the outstanding shares of Seer’s Class A common stock for $2.40 per share in cash plus a contingent value right (the “May 14 Revised Proposal”).
By Seer, Inc. · Via GlobeNewswire · May 21, 2026
NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 21, 2026
With up to 40 million monthly views across Reddit and Instagram, cult-favorite creator Miles Erickson’s breakout comic moves from digital phenomenon to physical publishing, consumer products, and multi-platform expansion.
By Salt Studio LLC · Via GlobeNewswire · May 21, 2026
New 56-bed Behavioral Health Center at Intermountain Alta View Hospital opens for patient care in June and doubles the number of patient beds for behavioral health care offered by Intermountain Health.
By Intermountain Health · Via GlobeNewswire · May 21, 2026
Santa Clara, CA and Kyoto, Japan, May 21, 2026 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced it has developed new Electro-Static Discharge (ESD) protection diodes – the RESDxVx series – that achieve both industry-leading low dynamic resistance (Rdyn) and ultra-low capacitance. This makes them suitable for a wide range of high-speed data communication applications.
By ROHM Semiconductor · Via GlobeNewswire · May 21, 2026
